ArticleMolecular biology reports2025
Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Expression of long non‑coding RNAs DIAPH3‑AS1, HMMR‑AS1, and SPATA3‑AS1 in patients with colorectal cancer: association with chemotherapy response and clinicopathological features.Molecular biology reports · 2026Article
- VPS9D1-AS1: a critical oncogenic long non-coding RNA in human malignancies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer.Frontiers in immunology · 2026Review
- The Role of Key Glycolytic Enzymes in the Diagnosis, Treatment, and Immune Microenvironment of Colorectal Cancer.Human mutation · 2025Review
- Transcriptome analysis and RT-qPCR validation of mitophagy-related key genes in the progression of diabetic retinopathy.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a significant cause of cancer-related mortality globally, primarily due to late-stage diagnoses. This study investigates the expression levels of antisense long non-coding RNAs (lncRNAs) RBM5-AS1, STEAP3-AS1, and VPS9D1-AS1 in both tissue and plasma samples from CRC patients to evaluate their potential as diagnostic biomarkers. Selection of these lncRNAs was based on prior studies indicating their dysregulation in CRC and their role in the Wnt/β-catenin signaling pathway, which modulates cell growth, apoptosis, and differentiation. MATERIALS AND
methodsThis experimental study included 40 plasma samples and 10 tissue samples from CRC patients, alongside an equal number of samples from healthy controls. The expression levels of the lncRNAs and β-catenin were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of these lncRNAs was evaluated through receiver operating characteristic (ROC) curve analysis on Plasma samples, which also facilitated the determination of optimal cutoff values.
resultsThe expression of the β-catenin gene was significantly elevated in CRC tissues (6.78-fold increase, p = 0.02) and plasma samples (4.79-fold increase, p < 0.001) compared to controls. Likewise, the expression levels of the lncRNAs were significantly higher in both CRC tissues and plasma samples relative to healthy subjects (p < 0.001). ROC curve analysis revealed robust predictive capabilities for the plasma expression of these lncRNAs, with area under the curve (AUC) values of 0.82 for STEAP3-AS1, 0.94 for VPS9D1-AS1, and 0.83 for RBM5-AS1.
conclusionThe findings indicate that the expression levels of β-catenin and lncRNAs STEAP3-AS1, VPS9D1-AS1, and RBM5-AS1 are significantly higher in both tissue and plasma samples from CRC patients compared to healthy individuals. Consequently, these lncRNAs may serve as promising biomarkers for CRC diagnosis. However, further studies are needed to validate these findings and explore additional applications.td.
Indexed as
Identifiers
40522493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.